Given the phenotypic differences given by IDH mutations in gliomas and its product 2-HG, which interferes in the Kreb’s Cycle, there is opportunity for exploration of the metabolic consequences of these mutations for GBMs. The gene discussed is IDH2; the disease is glioma.